News RSS Bioethics News.


Engineered cell therapy for cancer gets thumbs up from FDA advisers

External Link - Source: Nature

External advisers to the US Food and Drug Administration (FDA) have thrown their support behind a therapy that genetically engineers a patient’s own immune cells to target and destroy cancers. In a unanimous vote on 12 July, the panel determined that the benefits of CAR-T therapy outweigh its risks. The vote comes as the agency considers whether to issue its first approval of a CAR-T therapy, for a drug called tisagenlecleucel, manufactured by Novartis of Basel, Switzerland.

This entry was posted in Clinical Trials & Studies and tagged . Bookmark the permalink.